Market Cap $75 M --Cash $33 M -- 1 Drug launched in Europe --US market to follow soon (BLA filing in Q2 ) US-Partner already in place with Vericel (VCEL) ($150 M Deal) --Additional promising drugs in Pipeline --Strong Insider & institutional Ownership = Good Investment with great upside Potential ..Could hit $10-12 with FDA approval expected next year .GL Market-Cap $75 M Cash $33 M Price $2.80 Shares Out 27.18 M "Nick Colangelo, president and CEO of Vericel said, “After a successful pre-BLA meeting with the FDA, we remain on track for the BLA submission in the second quarter of 2020. NEXT will further extend the number of NexoBrid-trained physicians and healthcare providers in the U.S. and generate additional awareness, advocacy and use at U.S. burn centers prior to commercialization of NexoBrid." Presentation http://ir.mediwound.com/static-files/cd547017-d1ed-460e-8cb2-0550b1e18a29 Vericel Enters into Exclusive License Agreement with MediWound for North American Rights to NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns http://investors.vcel.com/news-rele...s-exclusive-license-agreement-mediwound-north Top Shareholders Clal ...9.4M Wellington ...2.9M Migdal Insurance ...2.1M Rosenberg (Lior) ...1.9M Yelin Lapidot ...1.7M Harel Insurance ...754.4K Renaissance ...286.9K Bank of ...226.2K Wells Fargo Advisors ...218.0K California ...211.5K
